Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma (COCP) highlights its innovative approach to developing antiviral therapeutics as flu and COVID season begins. The company's candidate CC-42344 shows activity against avian influenza A PB2 protein, while current vaccines offer no protection. Phase 2a study results for CC-42344 are expected by end of 2024. The company is also conducting a Phase 1 study of CDI-988, a pan-viral drug candidate for noroviruses and coronaviruses, with results expected late 2024 or early 2025. The company's platform technology targets highly conserved viral enzymes for developing broad-spectrum antivirals against seasonal and pandemic strains.

Cocrystal Pharma (Nasdaq: COCP) has initiated dosing in the multiple-ascending dose (MAD) portion of its Phase 1 study for CDI-988, an oral pan-viral protease inhibitor. This follows favorable results from the single-ascending dose (SAD) phase, which reported no serious adverse events. CDI-988, developed using Cocrystal’s proprietary drug discovery platform, targets viral gastroenteritis and COVID-19 caused by noroviruses and coronaviruses. The randomized, double-blind study in Australia evaluates the safety, tolerability, and pharmacokinetics of CDI-988 compared to a placebo in healthy adults. Topline results are expected in late 2024 or early 2025.

Cocrystal Pharma (Nasdaq: COCP) announces participation in two upcoming investment conferences to highlight near-term clinical milestones. The company expects to report topline results in 2024 from its influenza A Phase 2a challenge study with oral PB2 inhibitor CC-42344, with the final report expected in 2025. Additionally, topline results from the Phase 1 multiple-ascending cohorts for oral protease inhibitor CDI-988, targeting norovirus and coronavirus infections, are anticipated in late 2024 or early 2025.

The company will present at the Virtual Investor Summit Microcap Forum on August 20, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference starting September 9, 2024. These presentations will showcase Cocrystal's progress on their novel antiviral candidates, including CC-42344 for influenza A and CDI-988 for norovirus and coronavirus infections.

CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company focused on developing novel antiviral therapeutics, is set to present at the virtual Investor Summit Microcap Forum on August 20, 2024. The event, themed around 50 micro-cap companies with catalysts or strong market performance, offers a platform for CoCrystal's management to showcase their company overview at 9:00 a.m. ET.

The presentation will highlight CoCrystal's work in targeting the replication process of influenza viruses, coronaviruses, and noroviruses. Investors will have the opportunity to engage in live Q&A sessions and schedule one-on-one meetings with the management team throughout the day. This event provides a valuable opportunity for qualified investors to gain insights into CoCrystal's progress and potential in the antiviral therapeutics market.

Cocrystal Pharma (Nasdaq: COCP) reported Q2 2024 financial results and provided updates on its antiviral drug development programs. Key highlights include:

1. Expects topline results in 2025 from Phase 2a influenza A study with oral CC-42344
2. In vitro testing shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein
3. Anticipates topline results in late 2024/early 2025 from Phase 1 study with oral CDI-988
4. Plans to initiate Phase 1 study in 2025 with inhaled CC-42344

Financial results: Q2 2024 net loss of $5.3 million ($0.54 per share) compared to Q2 2023 net loss of $4.2 million ($0.41 per share). R&D expenses increased to $4.3 million from $2.8 million in Q2 2023. Cash position of $18.1 million as of June 30, 2024.

Cocrystal Pharma (Nasdaq: COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of its Phase 1 study for CDI-988, an oral pan-viral norovirus/coronavirus protease inhibitor. The study, conducted in Australia, evaluated doses ranging from 100 mg to 600 mg in healthy adults. Key findings include:

- No serious adverse events or severe treatment-emergent adverse events
- No clinically significant observations in laboratory assessments, physical exams, or electrocardiograms
- All participants completed the study with no discontinuations

CDI-988 is being developed as the first dual, broad-spectrum antiviral for norovirus and coronavirus treatment. The company plans to begin multiple-ascending dose (MAD) cohorts in Q4 2024.

Cocrystal Pharma (Nasdaq: COCP) has announced that its novel antiviral, CC-42344, shows promise against the highly pathogenic avian influenza A (H5N1) strain. Recent in vitro studies indicate that CC-42344 inhibits the influenza A virus's PB2 protein, essential for replication and transcription. The drug is currently in a Phase 2a clinical trial assessing its safety, tolerability, and antiviral benefits in influenza A patients, with top-line results expected in late 2024. Previously, a Phase 1 study in healthy volunteers demonstrated favorable safety and tolerability. The company used its proprietary structure-based platform to create a high-resolution crystal structure of the avian PB2 protein, confirming CC-42344's binding efficacy. The CDC has reported recent avian flu outbreaks in the U.S., including infections in dairy cows affecting humans.

Cocrystal Pharma, Inc. (Nasdaq: COCP) reports first-quarter 2024 financial results and updates on its antiviral drug-development programs. Topline results expected for Phase 1 oral CDI-988 and Phase 2a influenza A study. FDA feedback on CC-42344, initiation of Phase 1 study for inhaled CC-42344 planned. Positive cash flow management, $21.8 million cash on hand.

Cocrystal Pharma, Inc. completes enrollment of a Phase 2a study for its oral antiviral candidate CC-42344, aiming to combat pandemic and seasonal influenza. The study evaluated safety, tolerability, and antiviral effects of the drug. The company received positive Pre-IND feedback from the FDA for a proposed Phase 2b study. Cocrystal plans to start a Phase 1 study in Australia for an inhaled formulation of CC-42344. Recent preclinical data indicates promising results for the drug.